RT Journal Article
SR Electronic
T1 SARS-CoV-2 epidemic after social and economic reopening in three US states reveals shifts in age structure and clinical characteristics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.17.20232918
DO 10.1101/2020.11.17.20232918
A1 Nathan Wikle
A1 Thu Nguyen-Anh Tran
A1 Bethany Gentilesco
A1 Scott M Leighow
A1 Joseph Albert
A1 Emily R Strong
A1 Karel Břinda
A1 Haider Inam
A1 Fuhan Yang
A1 Sajid Hossain
A1 Philip Chan
A1 William P Hanage
A1 Maria Messick
A1 Justin R Pritchard
A1 Ephraim M Hanks
A1 Maciej F Boni
YR 2021
UL http://medrxiv.org/content/early/2021/11/06/2020.11.17.20232918.abstract
AB In the United States, state-level re-openings in spring 2020 presented an opportunity for the resurgence of SARS-CoV-2 transmission. One important question during this time was whether human contact and mixing patterns could increase gradually without increasing viral transmission, the rationale being that new mixing patterns would likely be associated with improved distancing, masking, and hygiene practices. A second key question to follow during this time was whether clinical characteristics of the epidemic would improve after the initial surge of cases. Here, we analyze age-structured case, hospitalization, and death time series from three states – Rhode Island, Massachusetts, and Pennsylvania – that had successful re-openings in May 2020 without summer waves of infection. Using a Bayesian inference framework on eleven daily data streams and flexible daily population contact parameters, we show that population-average mixing rates dropped by >50% during the lockdown period in March/April, and that the correlation between overall population mobility and transmission-capable mobility was broken in May as these states partially re-opened. We estimate the reporting rates (fraction of symptomatic cases reporting to health system) at 96.0% (RI), 72.1% (MA), and 75.5% (PA); in Rhode Island, when accounting for cases caught through general-population screening programs, the reporting rate estimate is 94.5%. We show that elderly individuals were less able to reduce contacts during the lockdown period when compared to younger individuals. Attack rate estimates through August 31 2020 are 6.4% (95% CI: 5.8% – 7.3%) of the total population infected for Rhode Island, 5.7% (95% CI: 5.0% – 6.8%) in Massachusetts, and 3.7% (95% CI: 3.1% – 4.5%) in Pennsylvania, with some validation available through published seroprevalence studies. Infection fatality rates (IFR) estimates for the spring epidemic are higher in our analysis (>2%) than previously reported values, likely resulting from the epidemics in these three states affecting the most vulnerable sub-populations, especially the most vulnerable of the ≥80 age group.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMFB, TNAT are funded by a grant from the Bill and Melinda Gates Foundation (INV-005517). FY is supported by the NIH/NIAID Center of Excellence in Influenza Research and Surveillance contract HHS N272201400007C. KB was partially supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number R35GM133700. WPH is funded by an award from the NIGMS (U54 GM088558). JA is funded by the Penn State MRSEC, Center for Nanoscale Science, NSF DMR-1420620. EH was partially supported by NSF DMS-2015273.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None needed. We are using aggregate data available from state DOH websites.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPosted on https://github.com/bonilab/public-covid19model https://github.com/bonilab/public-covid19model